A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes

References

• Adeghate E, Schattner P, Dunn E. (2006). An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 1084:1–29
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, et al. (2009). Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet 34:43–50
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, et al. (2012). Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet 37:99108
   Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. (2008a). Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep 60:532
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. (2008b). Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep 60:532–41
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. (2008c). Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Method Find Exp Clin Pharmacol 30:107–13
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. (2008d). Probiotic treatment proceeded by a single dose of bile acid and gliclazide exert the most hypoglycemic effect in Type 1 diabetic rats. Med Hypotheses Res 4:93–101
   Google Scholar
• Al-Salami H, Butt G, Tucker I, et al. (2008e). Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch Drug Inf 1:35–41
   PubMedGoogle Scholar
• Alam MJ, Rahman MA. (1971). Changes in the saccharoid fraction in rats with alloxan-induced diabetes or injected with epinephrine. Clin Chem 17:915–20
   PubMed Web of Science ®Google Scholar
• Barakat NS, Shazly GA, Almedany AH. (2013). Influence of polymer blends on the characterization of gliclazide – encapsulated into poly (epsilon–caprolactone) microparticles. Drug Dev Ind Pharm 39:352–62
   PubMed Web of Science ®Google Scholar
• Carvalho END, Carvalho NASD, Ferreira LM. (2003). Experimental model of induction of diabetes mellitus in rats. Acta Cirurg Brasil 18:60–4
   Google Scholar
• Chan KIA, Elkhider N, Kazarian SG. (2005). Spectroscopic imaging of compacted pharmaceutical tablets. Chem Eng Res Des 83:1303–10
   Web of Science ®Google Scholar
• Kazarian SG, Chan KLA. (2006). Applications of ATR-FTIR spectroscopic imaging to biomedical samples. Biochim Biophys Acta – Biomembr 1758:858–67
   PubMed Web of Science ®Google Scholar
• Kazarian SG, Kong KWT, Bajomo M, et al. (2005). Spectroscopic imaging applied to drug release. Food Bioprod Process 83:127–35
   Web of Science ®Google Scholar
• Khatun Z, Nurunnabi M, Reeck GR, et al. (2013). Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. J Control Release 170:74–82
   PubMed Web of Science ®Google Scholar
• Korec R. (1980). Treatment of alloxan and streptozotocin diabetes in rats by intrafamiliar homo (allo) transplantation of neonatal pancreases. Endocrinol Exp 14:191–8
   PubMedGoogle Scholar
• Lankin VZ, Korchin VI, Konovalova GG, et al. (2004). Role of antioxidant enzymes and antioxidant compound probucol in antiradical protection of pancreatic beta-cells during alloxan-induced diabetes. Bull Exp Biol Med 137:20–3
   PubMed Web of Science ®Google Scholar
• Lee E, Kim Y-S, Bae SM, et al. (2009). Polyproline-type helical-structured low-molecular weight heparin (LMWH)–taurocholate conjugate as a new angiogenesis inhibitor. Int J Cancer 124:2755–65
   PubMed Web of Science ®Google Scholar
• Mathews CE, Bagley R, Leiter EH. (2004). ALS/Lt: a new type 2 diabetes mouse model associated with low free radical scavenging potential. Diabetes 53:S125–9
   PubMed Web of Science ®Google Scholar
• Mikov M, Al-Salami H, Golocorbin-Kon S, et al. (2008). The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet 33:137–42
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Arfuso F, Al-Salami H. (2014a). Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic beta-cells. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. DOI:10.3109/21691401.2014.934457
   Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al. (2014b). Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Des Dev Ther 8:1003–12
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al. (2014c). Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Dev Ther 8:1221
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al. (2014d). An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Dev Ther 8:1673–83
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al. (2014e). An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Dev Ther 8:1673
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mathavan S, et al. (2014f). An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol 20:1–8
   Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mathavan S, et al. (2014g). An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol 20:702–9
   PubMed Web of Science ®Google Scholar
• Phillips P. (2005). Type 2 Diabetes-failure, blame and guilt in the adoption of insulin therapy. Rev Diabet Stud 2:35–9
   PubMedGoogle Scholar
• Prajapati VD, Mashru KH, Solanki HK, Jani GK. (2013). Development of modified release gliclazide biological macromolecules using natural biodegradable polymers. Int J Biol Macromol 55:6–14
   PubMed Web of Science ®Google Scholar
• Rakel A, Renier G, Roussin A, et al. (2007). Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes Metab 9:127–9
   PubMed Web of Science ®Google Scholar
• Rokstad AMA, Lacík I, De Vos P, Strand BL. (2014). Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation. Adv Drug Deliv Rev 67–68:111–30
   PubMed Web of Science ®Google Scholar
• Sartori C, Finch DS, Ralph B, Gilding K. (1997). Determination of the cation content of alginate thin films by FTIR spectroscopy. Polymer 38:43–51
   Web of Science ®Google Scholar
• Stetinova V, Kvetina J, Pastera J, et al. (2007). Gliclazide: pharmacokinetic-pharmacodynamic relationships in rats. Biopharm Drug Dispos 28:241–8
   PubMed Web of Science ®Google Scholar
• Tsiani E, Ramlal T, Leiter LA, et al. (1995). Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology 136:2505–12
   PubMed Web of Science ®Google Scholar
• Weiss R, Caprio S. (2006). Development of type 2 diabetes in children and adolescents. Minerva Med 97:263–9
   PubMedGoogle Scholar
• Xu W, Ling P, Zhang T. (2013). Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv 2013:340315. DOI: 10.1155/2013/340315
   Google Scholar
• Yang L, Xu Y, Su Y, et al. (2005). FT-IR spectroscopic study on the variations of molecular structures of some carboxyl acids induced by free electron laser. Spectrochim Acta Part A Mol Biomol Spectrosc 62:1209–15
   PubMed Web of Science ®Google Scholar